Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;6(1):46-53.
doi: 10.1007/s12265-012-9413-4. Epub 2012 Oct 16.

iPS Cell Modeling of Cardiometabolic Diseases

Affiliations
Free PMC article
Review

iPS Cell Modeling of Cardiometabolic Diseases

Kenta Nakamura et al. J Cardiovasc Transl Res. .
Free PMC article

Abstract

Cardiometabolic diseases encompass simple monogenic enzyme deficiencies with well-established pathogenesis and clinical outcomes to complex polygenic diseases such as the cardiometabolic syndrome. The limited availability of relevant human cell types such as cardiomyocytes has hampered our ability to adequately model and study pathways or drugs relevant to these diseases in the heart. The recent discovery of induced pluripotent stem (iPS) cell technology now offers a powerful opportunity to establish translational platforms for cardiac disease modeling, drug discovery, and pre-clinical testing. In this article, we discuss the excitement and challenges of modeling cardiometabolic diseases using iPS cell and their potential to revolutionize translational research.

Figures

Figure 1
Figure 1. An overview of common mechanisms in cardiometabolic disease

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Supplementary concepts

Feedback